GPCR's are involved in a variety of diseases spanning a range of therapeutic areas and have historically been the domain of small molecule drugs. Recent technological advances have opened the possibility to develop therapeutic human monoclonal antibodies in multiple disease areas, conferring additional benefits such as specificity and longer duration of action. FPR1 is a Class A GPCR and is activated by N-formylated peptides (FPR), which can be released by bacterial colonization and lung tissue damage which are common features of chronic obstructive pulmonary disease (COPD). FPR1 presents a potentially attractive target for an antibody based therapeutic approach. This poster demonstrates the use of a fluorescent FPR ligand to develop ligand binding and internalisation assays used for screening, and profiling anti-FPR1 antibodies in cell based assays.